![Thomas Taapken](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Taapken
Directeur Financier/CFO chez
INFLARX N.V.
Fortune : 8 400 $ au 31/05/2026
Profil
Thomas Taapken currently works at Bluehaven Therapeutics AG, as Chief Executive Officer, ImCyse SA, as Chairman from 2019, SciBase AB, as Director from 2017, elbion NV, as Chief Financial Officer, and InflaRx NV, as Chief Financial Officer from 2020.
Dr. Taapken also formerly worked at Biotie Therapies Oy, as CEO, CFO & Investor Relations Contact from 2008 to 2011, Immunic AG, as Director, SciBase Holding AB, as Independent Director, Memo Therapeutics AG, as Independent Director from 2021 to 2023, Burrill LLC, as Partner from 1998 to 2002, MediGene AG, as Chief Executive & Financial Officer from 2017 to 2018, Epigenomics AG, as Chief Executive & Financial Officer from 2011 to 2016, DVC Deutsche Venture Capital, as Partner, elbion AG, as Chief Financial Officer in 2007, and Sanofi-Aventis Deutschland GmbH, as Principal.
Dr. Taapken received his doctorate degree in 1994 from Technical University of Berlin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INFLARX N.V. 0 % | 18/03/2026 | 3 500 ( 0 % ) | 8 400 $ | 31/05/2026 |
Postes actifs de Thomas Taapken
| Sociétés | Poste | Début |
|---|---|---|
| INFLARX N.V. | Directeur Financier/CFO | 01/10/2020 |
elbion NV
 elbion NV Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for neurological diseases | Directeur Financier/CFO | - |
ImCyse SA
 ImCyse SA BiotechnologyHealth Technology Engages in the development of curative therapies in the field of immune and allergic pathologies | Président | 01/01/2019 |
Bluehaven Therapeutics AG | Directeur Général | - |
Scibase AB | Directeur/Membre du Conseil | 01/01/2017 |
Anciens postes connus de Thomas Taapken
| Sociétés | Poste | Fin |
|---|---|---|
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Develops a disruptive platform technology for antibody discovery | Directeur/Membre du Conseil | 01/12/2023 |
| MEDIGENE AG | Directeur Général | 31/08/2018 |
| EPIGENOMICS AG | Directeur Général | 30/06/2016 |
| BIOTIE THERAPIES CORP | Directeur Général | 01/04/2011 |
| ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Thomas Taapken
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
70
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
elbion NV
elbion NV Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for neurological diseases | Health Technology |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burrill invests in companies located in the United States. The firm focuses on a broad range of sectors. It participates in buyout and early-stage transactions. | Finance |
MediGene AG
 MediGene AG BiotechnologyHealth Technology Engages in the clinical research and development of novel drugs against cancer & autoimmune diseases with focus on personalized immunotherapies | Health Technology |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Epigenomics AG
 Epigenomics AG Medical SpecialtiesHealth Technology Engages in the development and commercialization of in vitro diagnostic tests for cancer | Health Technology |
DVC Deutsche Venture Capital
 DVC Deutsche Venture Capital Investment ManagersFinance DVC is a venture capital investment manager focused on European high-growth, early-stage companies with global expansion potential. The firm invests in sectors including life sciences, information technology, telecommunication, semiconductor and industrial technologies. In the field of life sciences, DVC invests specifically in the development of therapeutic products, diagnostics, medical devices and biotechnology platforms. Their technology investments target businesses whose activity pertains to 1) the management of information, applications and infrastructure, 2) communication applications and platforms as well as network infrastructure, and 3) technologies related to optics, automation, sensors, electronics, semiconductors and materials. DVC aims to leverage their access to Deutsche Bank's international network and lead their portfolio companies from technological leadership to international market success. Investment criteria include distinctive technology with adequate IP protection and addressing a clearly identified market, an experienced management team and leadership potential in high-growth markets internationally. The firm is generally the lead investor in German-speaking countries, and co-leads in other European countries and the US. They aim to keep their portfolio balanced across their target sectors and across development stages, with a majority of early-stage investments complemented with expansion-phase investments with short-term exit potential. DVC actively assists their portfolio companies with financial issues, key hires and marketing strategy without interfering in operational management. | Finance |
SciBase Holding AB
 SciBase Holding AB Medical SpecialtiesHealth Technology Develops point of care device for the detection of malignant melanoma | Health Technology |
elbion AG
 elbion AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops new small molecule drugs | Commercial Services |
Technical University of Berlin
 Technical University of Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi-Aventis Deutschland GmbH
 Sanofi-Aventis Deutschland GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products & provides research and development services | Health Technology |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology Engages in the development of curative therapies in the field of immune and allergic pathologies | Health Technology |
Scibase AB | |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Develops a disruptive platform technology for antibody discovery | Health Technology |
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals in the immunology space | Health Technology |
InflaRx NV
 InflaRx NV BiotechnologyHealth Technology Develops biopharmaceutical products | Health Technology |
Bluehaven Therapeutics AG |
